Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Daniela, Alberati"'
Publikováno v:
CHIMIA, Vol 72, Iss 7-8 (2018)
Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness. More recently, preclin
Externí odkaz:
https://doaj.org/article/8c0a3d50696a46f38ab15715e29fc2a6
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 107:148-156
Bitopertin is a glycine type 1 (GlyT1) inhibitor intended for the treatment of psychiatric disorders. The principle adverse effect in the regulatory reproductive toxicity studies was peri-natal pup death when rat dams were treated during parturition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::883384b97b95886a22d96fa96480883f
https://doi.org/10.1002/bdrb.21179
https://doi.org/10.1002/bdrb.21179
Publikováno v:
CHIMIA, Vol 72, Iss 7-8 (2018)
Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness. More recently, preclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69985248692d0c95eb3ca918e75ec4a
https://www.chimia.ch/chimia/article/view/1465
https://www.chimia.ch/chimia/article/view/1465
Autor:
Anton Bespalov, Daniela Alberati, Rainer Spanagel, Tatiane T. Takahashi, Berthold Behl, Martin Roßmanith, Valentina Vengeliene
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 365(1)
It has recently been demonstrated that pharmacological blockade of the glycine transporter 1 (GlyT1) reduced alcohol intake and relapse in rats. The aim of the present study was to further explore the role of GlyT1 in alcohol relapse-like behavior. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::668de3103358491a2b059d188ca7eb53
https://pubmed.ncbi.nlm.nih.gov/29367277
https://pubmed.ncbi.nlm.nih.gov/29367277
Autor:
Susanne Ostrowitzki, John Hilton, Robert F. Dannals, Dean F. Wong, Edilio Borroni, Dominik Hainzl, Anil Kumar, Yun Zhou, Thomas Hartung, Daniela Alberati
Publikováno v:
NeuroImage. 75:291-300
A specific positron emission tomography (PET) radiotracer for the glycine transporter type 1 (GlyT1) would constitute an imaging biomarker to investigate the distribution of GlyT1 in normal individuals and those with neuropsychiatric disorders. In ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b154a5c9d16e18f438f1930ffa5a4e
https://doi.org/10.1016/j.neuroimage.2011.11.090
https://doi.org/10.1016/j.neuroimage.2011.11.090
Rationale Motivated behavior can be characterized by a substantial exertion of effort, and organisms often make effortrelated decisions based upon analyses of work-related response costs and reinforcement preference. Moreover, alterations in effort-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c314766b12d17bb5e26bc8eedecb0ae0
Publikováno v:
Birth defects research. Part B, Developmental and reproductive toxicology. 107(3)
Bitopertin is a glycine type 1 (GlyT1) inhibitor intended for the treatment of psychiatric disorders. The principle adverse effect in the regulatory reproductive toxicity studies was peri-natal pup death when rat dams were treated during parturition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::440eb0912292b26d86a6b076f21412fc
https://pubmed.ncbi.nlm.nih.gov/27221585
https://pubmed.ncbi.nlm.nih.gov/27221585
Autor:
Joseph G. Wettstein, Bríd Á. Nic Dhonnchadha, Daniela Alberati, Roger D. Spealman, Emmanuel Pinard, Kathleen M. Kantak
Publikováno v:
Drug and Alcohol Dependence. 122:119-126
Combining extinction training with cognitive-enhancing pharmacotherapy represents a novel strategy for improving the efficacy of exposure therapy for drug relapse prevention. We investigated if the selective glycine transporter-1 (GlyT-1) inhibitor R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2542053170302c08751d7748e6301fa
https://doi.org/10.1016/j.drugalcdep.2011.09.017
https://doi.org/10.1016/j.drugalcdep.2011.09.017
Publikováno v:
Pharmacology Biochemistry and Behavior. 97:185-191
Multiple lines of evidence support the notion that hypofunction of glutamatergic neurotransmission is involved in the pathophysiology of schizophrenia. Moreover, glycine and glycine modulators have beneficial effects in patients with schizophrenia, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d7c1a887d1102ad71c16c9d2ca45da
https://doi.org/10.1016/j.pbb.2010.07.016
https://doi.org/10.1016/j.pbb.2010.07.016
Autor:
Andrew Thomas, Jean-Luc Moreau, Matthias Nettekoven, Daniela Alberati, Holger Fischer, Roger David Norcross, Edilio Borroni, Henri Stalder, Robert Narquizian, Emmanuel Pinard, Dominik Hainzl, Synese Jolidon
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:5134-5139
Screening of the Roche compound library led to the identification of the benzoylpiperazine 7 as a structurally novel GlyT1 inhibitor. The SAR which was developed in this series resulted in the discovery of highly potent compounds displaying excellent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f2de0420610c11e3f5ebe963dbef982
https://doi.org/10.1016/j.bmcl.2008.07.086
https://doi.org/10.1016/j.bmcl.2008.07.086